| Fruquintinib studied in …STUDIED_INderived89 of 89show fewer |
|---|
| → studied in | NCT07819019Phase 2 · not yet recruiting A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer · 89 trials list this drug (44 active) | — | — | Gastric Neoplasm,Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07791758Phase 1/Phase 2 · not yet recruiting A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma · 89 trials list this drug (44 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06992258Phase 2 · recruiting A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07730489Phase 3 · not yet recruiting A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and Irinotecan · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07235293Phase 2 · recruiting A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06484153Phase 2 · recruiting Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07136077Phase 2 · active not recruiting A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06417892recruiting Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma · 89 trials list this drug (44 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05848739Phase 1 · active not recruiting A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors · 89 trials list this drug (44 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06562543Phase 4 · recruiting A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07011576Phase 2 · recruiting A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL) · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm,Malignant Colon Neoplasm,Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05941325Phase 2 · suspended A Single-arm, Open-label, Single-center Prospective Study of Fruquintinib Combined With Envafolimab in the Treatment of Advanced or Unresectable Locally Advanced Bone and Soft Tissue Sarcoma · 89 trials list this drug (44 active) | — | — | Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04164199Phase 3 · completed Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07621159Phase 1/Phase 2 · not yet recruiting A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced Colorectal Cancer · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07124858NA · recruiting Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07591597Phase 1/Phase 2 · not yet recruiting A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07510932Phase 2 · not yet recruiting Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K) · 89 trials list this drug (44 active) | — | — | Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502014Phase 2 · not yet recruiting A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06497985Phase 3 · recruiting A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07446465Phase 4 · not yet recruiting FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07392346Phase 2 · recruiting Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07270991Phase 3 · recruiting Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05867420Phase 1/Phase 2 · recruiting A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. · 89 trials list this drug (44 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05954429Phase 2 · recruiting A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-limited Metastatic Colorectal Cancer: a Single-center, Phase 2 Study · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06856837Phase 2 · recruiting - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07229872Phase 2 · not yet recruiting A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07130903Phase 2 · recruiting Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Colorectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07170982Phase 2 · not yet recruiting Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer · 89 trials list this drug (44 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07150403Phase 2 · not yet recruiting Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06441565Phase 2/Phase 3 · recruiting Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04577963Phase 1/Phase 2 · terminated A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors · 89 trials list this drug (44 active) | — | — | Adult Solid Neoplasm,Malignant Colorectal Neoplasm,Triple-Negative Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05771181Phase 2 · recruiting Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm,Microsatellite Stable Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973421Phase 2 · not yet recruiting Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Cancer · 89 trials list this drug (44 active) | — | — | Platinum-Resistant Ovarian Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04322539Phase 3 · completed A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm,Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04716634Phase 2 · completed Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors · 89 trials list this drug (44 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06791083Phase 2 · recruiting Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer · 89 trials list this drug (44 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06427005Phase 2 · unknown Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06774222Phase 2 · recruiting A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06584032Phase 3 · recruiting Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer · 89 trials list this drug (44 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05522231Phase 2/Phase 3 · active not recruiting Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2) · 89 trials list this drug (44 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06446154Phase 2 · recruiting Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma · 89 trials list this drug (44 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06685276Phase 2 · recruiting Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06646588Phase 2 · recruiting Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma · 89 trials list this drug (44 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03251378Phase 1 · completed A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers · 89 trials list this drug (44 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Hormone Receptor-Positive Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06613113NA · recruiting Fruquintinib Combined With Adebrelimab and High and Low Dose Radiotherapy in the Treatment of Second-line and Above Failure MSS Metastatic Colorectal Cancer. · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05625737Phase 2 · unknown Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction Adenocarcinoma · 89 trials list this drug (44 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06551207NA · recruiting Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06543836Phase 2 · unknown ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06347198early Phase 1 · unknown Oral Inulin in Combination With Fruquintinib Plus Sintilimab as Third- or Further-line Treatment in Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06218888Phase 2 · not yet recruiting A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases · 89 trials list this drug (44 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05435313Phase 2 · unknown Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06202599completed Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance · 89 trials list this drug (44 active) | — | — | Neoplasm,Bone Sarcoma,Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06202417completed Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06168786Phase 2 · recruiting Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06118762Phase 4 · recruiting Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06094868Phase 2 · not yet recruiting Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer · 89 trials list this drug (44 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06031376completed Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC · 89 trials list this drug (44 active) | — | — | Colorectal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06018714Phase 2 · unknown Efficacy of Modified Fruquintinib in Colorectal Cancer Liver Metastases: A Phase II Study · 89 trials list this drug (44 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05795296Phase 2 · unknown Efficacy and Safety of Fruquintinib With Sintilimab as First-line Therapy in Gastric Cancer · 89 trials list this drug (44 active) | — | — | Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05914610Phase 3 · not yet recruiting Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer · 89 trials list this drug (44 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05993702unknown TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05971199Phase 2 · unknown Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma · 89 trials list this drug (44 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025631Phase 2 · completed A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC） · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05763927Phase 2 · unknown Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT · 89 trials list this drug (44 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05643677Phase 2 · unknown Fruquintinib Plus Irinotecan in the Treatment of Advanced Gastric Cancer · 89 trials list this drug (44 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05634590Phase 2 · unknown The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05368805Phase 1 · completed Fruquintinib DDI Study With P-gp and BCRP Substrates · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05511051Phase 2 · unknown A Prospective Multi-centered Randomized Controlled Trial on Fruquintinib in Combination With HAIC in the Treatment of Liver Metastatic Colorectal Cancer After Failure of Second-line Systematic Therapy · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05447715Phase 2 · unknown Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05406206Phase 2 · unknown Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy · 89 trials list this drug (44 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05292417Phase 2 · unknown Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC · 89 trials list this drug (44 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05142631Phase 2 · unknown Fruquintinib in the Treatment of Soft Tissue Sarcoma · 89 trials list this drug (44 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05257122Phase 2 · unknown A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer · 89 trials list this drug (44 active) | — | — | Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04296019Phase 2 · unknown Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04582981Phase 2 · unknown Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Colorectal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04948034Phase 2 · unknown The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03976856Phase 1 · unknown Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib · 89 trials list this drug (44 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03977090Phase 1 · unknown Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02196688Phase 2 · completed Study of Fruquintinib in Patients With Metastatic Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04431791unknown Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01645215Phase 1 · completed Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors · 89 trials list this drug (44 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01975077Phase 1/Phase 2 · completed A Phase Ib Study of Fruquintinib in 3rd Line mCRC · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314819Phase 3 · completed A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO) · 89 trials list this drug (44 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02590965Phase 2 · completed A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer · 89 trials list this drug (44 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04179084Phase 2 · unknown Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer · 89 trials list this drug (44 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03684967Phase 2 · withdrawn Study of Fruquintinib (HMPL-013) in High Risk Patients With Advanced NSCLC · 89 trials list this drug (44 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02976116Phase 2 · completed A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer · 89 trials list this drug (44 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04156958Phase 2 · unknown Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma · 89 trials list this drug (44 active) | — | — | Biliary Tract Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02691299Phase 3 · completed A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer · 89 trials list this drug (44 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |